title: Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study.
abstract: OBJECTIVE
  Data on the durability of antiretroviral regimens over a 3-year period have only rarely been reported. The aim of this study was to evaluate the long-term efficacy and safety of one or two daily doses of nevirapine (NVP), in combination with stavudine (d4T) and didanosine (ddI), in HIV-infected patients.
  
  
  METHODS
  This study was a follow-up of the VIR (amune) Grand Ouest (VIRGO) study, a 12-month open-label trial to assess the safety and immunovirological activity of NVP-d4T-ddI combination therapy in antiretroviral-naive HIV-1-infected adults with baseline CD4 counts > or =200 cells/microL and plasma viral loads > or =5000 HIV-1 RNA copies/mL. Of the 100 patients included in the study, the 67 patients remaining on the initial triple therapy at the end of the study (1 year) were offered an extra 24 months of follow-up.
  
  
  RESULTS
  Of the 60 patients who extended follow-up, 46 were still being treated with d4T-ddI-NVP at month 36; 91% (39/43) had a plasma viral load <500 copies/mL (data were missing for three patients). CD4 cell counts increased over 36 months. Safety and tolerance were good with no unexpected long-term toxicity.
  
  
  CONCLUSIONS
  After 3 years of treatment with NVP-d4T-ddI, nearly half of the patients were still receiving the initial antiretroviral therapy with a sustained and durable immunovirological benefit. Long-term toxicity was mainly related to the nucleoside reverse transcriptase inhibitor components of the regimen.
authors.affiliation: Service des Maladies Infectieuses et Tropicales, Hôpital Hôtel-Dieu, Nantes, France. veronique.reliquet@chu-nantes.fr
authors.forename: V
authors.initials: V
authors.lastname: Reliquet
authors.forename: C
authors.initials: C
authors.lastname: Allavena
authors.forename: C
authors.initials: C
authors.lastname: François-Brunet
authors.forename: P
authors.initials: P
authors.lastname: Perré
authors.forename: V
authors.initials: V
authors.lastname: Bellein
authors.forename: M
authors.initials: M
authors.lastname: Garré
authors.forename: T
authors.initials: T
authors.lastname: May
authors.forename: F
authors.initials: F
authors.lastname: Souala
authors.forename: J-M
authors.initials: JM
authors.lastname: Besnier
authors.forename: F
authors.initials: F
authors.lastname: Raffi
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D016049:Didanosine / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D005602:France; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D019829:Nevirapine / Q000627:therapeutic use*; D018119:Stavudine / Q000627:therapeutic use; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D019829:Nevirapine; D018119:Stavudine; D016049:Didanosine